ES2468391T3 - Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20 - Google Patents
Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20 Download PDFInfo
- Publication number
- ES2468391T3 ES2468391T3 ES09795585.0T ES09795585T ES2468391T3 ES 2468391 T3 ES2468391 T3 ES 2468391T3 ES 09795585 T ES09795585 T ES 09795585T ES 2468391 T3 ES2468391 T3 ES 2468391T3
- Authority
- ES
- Spain
- Prior art keywords
- pyrimido
- chloro
- phenyl
- benzoazepin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003719 aurora kinase inhibitor Substances 0.000 title claims abstract description 58
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 44
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 230000002489 hematologic effect Effects 0.000 claims abstract description 13
- 229960004641 rituximab Drugs 0.000 claims description 198
- -1 -OH Chemical group 0.000 claims description 181
- 206010028980 Neoplasm Diseases 0.000 claims description 77
- 125000001931 aliphatic group Chemical group 0.000 claims description 74
- 125000003118 aryl group Chemical group 0.000 claims description 67
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 64
- 125000001072 heteroaryl group Chemical group 0.000 claims description 63
- 125000000623 heterocyclic group Chemical group 0.000 claims description 59
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 24
- 206010025323 Lymphomas Diseases 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000001475 halogen functional group Chemical group 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000006162 fluoroaliphatic group Chemical group 0.000 claims description 14
- 125000003107 substituted aryl group Chemical group 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 102000004000 Aurora Kinase A Human genes 0.000 claims description 8
- 108090000461 Aurora Kinase A Proteins 0.000 claims description 8
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 239000005441 aurora Substances 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 108091000080 Phosphotransferase Proteins 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 102000020233 phosphotransferase Human genes 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims description 2
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical group C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 125000006519 CCH3 Chemical group 0.000 claims description 2
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims description 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 242
- 238000011282 treatment Methods 0.000 description 161
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 119
- 239000003981 vehicle Substances 0.000 description 80
- 239000005711 Benzoic acid Substances 0.000 description 57
- 230000004614 tumor growth Effects 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 43
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 38
- 230000004083 survival effect Effects 0.000 description 38
- 125000001424 substituent group Chemical group 0.000 description 34
- 230000008859 change Effects 0.000 description 32
- 239000000654 additive Substances 0.000 description 31
- 230000000996 additive effect Effects 0.000 description 30
- 230000000694 effects Effects 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 230000005764 inhibitory process Effects 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 27
- 108090000433 Aurora kinases Proteins 0.000 description 23
- 102000003989 Aurora kinases Human genes 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 238000011284 combination treatment Methods 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 150000001721 carbon Chemical group 0.000 description 19
- 230000002195 synergetic effect Effects 0.000 description 18
- 230000007423 decrease Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 14
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 14
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 125000001841 imino group Chemical group [H]N=* 0.000 description 14
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 125000006413 ring segment Chemical group 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 238000004364 calculation method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000012417 linear regression Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000011579 SCID mouse model Methods 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- GJPUTKWVQJEZPE-UHFFFAOYSA-N 1h-azepin-2-amine Chemical compound NC1=CC=CC=CN1 GJPUTKWVQJEZPE-UHFFFAOYSA-N 0.000 description 7
- 241000021375 Xenogenes Species 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- CUJJWOUYYROEOP-UHFFFAOYSA-N 2-benzazepin-2-amine Chemical compound NN1C=CC=C2C=CC=CC2=C1 CUJJWOUYYROEOP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- XGVUVRIEWOJBIV-UHFFFAOYSA-N C1(CCCC1)C(=O)NN(C)C Chemical compound C1(CCCC1)C(=O)NN(C)C XGVUVRIEWOJBIV-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000029918 bioluminescence Effects 0.000 description 5
- 238000005415 bioluminescence Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012066 statistical methodology Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- JZFSLMDLIPKTAO-UHFFFAOYSA-N 1,3-dihydroazepin-2-one Chemical compound O=C1CC=CC=CN1 JZFSLMDLIPKTAO-UHFFFAOYSA-N 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- LJCJRRKKAKAKRV-UHFFFAOYSA-N (2-amino-2-methylpropyl) 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical group CC(C)(N)COC(=O)CCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 LJCJRRKKAKAKRV-UHFFFAOYSA-N 0.000 description 2
- UAHSNMUZFDALCC-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 UAHSNMUZFDALCC-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000006161 haloaliphatic group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ZXHKEZLQGUTIEG-UHFFFAOYSA-N (2-aminopiperidin-1-yl)-[4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound NC1CCCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 ZXHKEZLQGUTIEG-UHFFFAOYSA-N 0.000 description 1
- JIAGXOBZNQXQLP-UHFFFAOYSA-N (3,5-dimethylpiperazin-1-yl)-[7-(2-fluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepin-9-yl]methanone Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(=O)N2CC(C)NC(C)C2)=C1 JIAGXOBZNQXQLP-UHFFFAOYSA-N 0.000 description 1
- YFOPJKDUOQWITF-UHFFFAOYSA-N (3-amino-3-methylpyrrolidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(C)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 YFOPJKDUOQWITF-UHFFFAOYSA-N 0.000 description 1
- PSKCHRFIACXCCL-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 PSKCHRFIACXCCL-UHFFFAOYSA-N 0.000 description 1
- HDMPGHZWDQUVFB-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(N)C2)C=C1 HDMPGHZWDQUVFB-UHFFFAOYSA-N 0.000 description 1
- SDVVHBZKMLWYNA-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 SDVVHBZKMLWYNA-UHFFFAOYSA-N 0.000 description 1
- RNJBXXMWQRHYPF-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C(F)(F)F)C=2C3=CC=C(Cl)C=2)C3=N1 RNJBXXMWQRHYPF-UHFFFAOYSA-N 0.000 description 1
- QSSNZICYKMCABB-UHFFFAOYSA-N (3-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QSSNZICYKMCABB-UHFFFAOYSA-N 0.000 description 1
- BABUYKSWUCYTGK-UHFFFAOYSA-N (3-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(N)CCC2)C=C1 BABUYKSWUCYTGK-UHFFFAOYSA-N 0.000 description 1
- DEARBBFOQKBFIU-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DEARBBFOQKBFIU-UHFFFAOYSA-N 0.000 description 1
- HPYDSNMHEKEDBX-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 HPYDSNMHEKEDBX-UHFFFAOYSA-N 0.000 description 1
- NRDJDXOZPPABNZ-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 NRDJDXOZPPABNZ-UHFFFAOYSA-N 0.000 description 1
- MRBHGHQGGUMGKT-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(N)CC2)C=C1 MRBHGHQGGUMGKT-UHFFFAOYSA-N 0.000 description 1
- ARKMPIXDDGNXPT-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 ARKMPIXDDGNXPT-UHFFFAOYSA-N 0.000 description 1
- ZRVLNNOPDZFOTR-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-[4-[[9-chloro-7-(3-fluoropyridin-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CN=2)F)C3=N1 ZRVLNNOPDZFOTR-UHFFFAOYSA-N 0.000 description 1
- QLSJWRRLRFNQPS-UHFFFAOYSA-N (4-amino-4-methylpiperidin-1-yl)-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(C)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QLSJWRRLRFNQPS-UHFFFAOYSA-N 0.000 description 1
- WOAKHDUKZKTQBK-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1Cl WOAKHDUKZKTQBK-UHFFFAOYSA-N 0.000 description 1
- WDPNHDXDQKINDC-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 WDPNHDXDQKINDC-UHFFFAOYSA-N 0.000 description 1
- GQKCTBSEWQDSQQ-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCC(N)CC2)C=C1 GQKCTBSEWQDSQQ-UHFFFAOYSA-N 0.000 description 1
- YRGWWSZGYSMKIX-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YRGWWSZGYSMKIX-UHFFFAOYSA-N 0.000 description 1
- OBWQYRODSNUXCN-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[[9-chloro-7-(3-fluoropyridin-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1CC(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CN=2)F)C3=N1 OBWQYRODSNUXCN-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SUPNGXZXBSSNNZ-UHFFFAOYSA-N 1-(1,4-dioxan-2-yl)piperidine Chemical compound C1CCCCN1C1OCCOC1 SUPNGXZXBSSNNZ-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- BMOGXCUMOSRQRR-UHFFFAOYSA-N 1-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-3,5,5-trimethylpiperazin-2-one Chemical compound O=C1C(C)NC(C)(C)CN1C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 BMOGXCUMOSRQRR-UHFFFAOYSA-N 0.000 description 1
- CXEPBVHUNMONEQ-UHFFFAOYSA-N 1-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-3-(dimethylamino)propan-1-one Chemical compound CN(C)CCC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 CXEPBVHUNMONEQ-UHFFFAOYSA-N 0.000 description 1
- OITHRBNKPHWCOB-UHFFFAOYSA-N 1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 OITHRBNKPHWCOB-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 description 1
- DXUMDXDNZIAPHG-UHFFFAOYSA-N 2-(4-carbamoylanilino)-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(C=2)C(O)=O)C=2C(=CC=CC=2F)F)C3=N1 DXUMDXDNZIAPHG-UHFFFAOYSA-N 0.000 description 1
- FCZCZXISRXYSAW-UHFFFAOYSA-N 2-(4-carboxyanilino)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(C=2)C(O)=O)C3=N1 FCZCZXISRXYSAW-UHFFFAOYSA-N 0.000 description 1
- LJYTXCGWRBZLJH-UHFFFAOYSA-N 2-(aminomethyl)-n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-1,3-benzoxazol-5-amine Chemical compound C=1C=C2OC(CN)=NC2=CC=1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F LJYTXCGWRBZLJH-UHFFFAOYSA-N 0.000 description 1
- HDWYKJPTZKCUEW-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetamide Chemical compound NC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)Cl)=NCC3=CN=2)=C1 HDWYKJPTZKCUEW-UHFFFAOYSA-N 0.000 description 1
- UXMDAZZNAZVUHG-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)Cl)=NCC3=CN=2)=C1 UXMDAZZNAZVUHG-UHFFFAOYSA-N 0.000 description 1
- JGEWBEAFEKNGIN-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n-[3-(4-methylpiperazin-1-yl)propyl]acetamide Chemical compound C1CN(C)CCN1CCCNC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 JGEWBEAFEKNGIN-UHFFFAOYSA-N 0.000 description 1
- JTAXVNQSWTUGCT-UHFFFAOYSA-N 2-[3-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)=C1 JTAXVNQSWTUGCT-UHFFFAOYSA-N 0.000 description 1
- CBLVDMAMRWPFLY-UHFFFAOYSA-N 2-[4-(3,5-dimethylpiperazine-1-carbonyl)anilino]-9-methoxy-5,6-dihydropyrimido[5,4-d][2]benzazepin-7-one Chemical compound C=1C(OC)=CC=C(C2=N3)C=1C(=O)NCC2=CN=C3NC(C=C1)=CC=C1C(=O)N1CC(C)NC(C)C1 CBLVDMAMRWPFLY-UHFFFAOYSA-N 0.000 description 1
- XAXVVZPCVKGVDJ-UHFFFAOYSA-N 2-[4-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazin-1-yl]-1-morpholin-4-ylethanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CC(=O)N3CCOCC3)CC2)C=C1 XAXVVZPCVKGVDJ-UHFFFAOYSA-N 0.000 description 1
- VCGZPJSQGKBQNN-UHFFFAOYSA-N 2-[4-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 VCGZPJSQGKBQNN-UHFFFAOYSA-N 0.000 description 1
- YFXWSZOXHWBHRT-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-1,4,5,6-tetrahydropyrimidin-5-ol Chemical compound C1C(O)CNC(C=2C=CC(NC=3N=C4C5=CC=C(Cl)C=C5C(=NCC4=CN=3)C=3C(=CC=CC=3F)F)=CC=2)=N1 YFXWSZOXHWBHRT-UHFFFAOYSA-N 0.000 description 1
- RHHGRLUONLSEPM-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n-(2-morpholin-4-ylethyl)acetamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC(C=C1)=CC=C1CC(=O)NCCN1CCOCC1 RHHGRLUONLSEPM-UHFFFAOYSA-N 0.000 description 1
- QPUOXZLCRHZPSB-UHFFFAOYSA-N 2-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 QPUOXZLCRHZPSB-UHFFFAOYSA-N 0.000 description 1
- RHEKNYLNBLOXOL-UHFFFAOYSA-N 2-[[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]amino]butanedioic acid Chemical compound C1=CC(C(=O)NC(CC(=O)O)C(O)=O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RHEKNYLNBLOXOL-UHFFFAOYSA-N 0.000 description 1
- IPRIHHMBMGPDQU-UHFFFAOYSA-N 2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methyl-1,3-thiazole-4-carboxamide Chemical compound CNC(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 IPRIHHMBMGPDQU-UHFFFAOYSA-N 0.000 description 1
- MWLFQGAIUUZLMF-UHFFFAOYSA-N 2-amino-n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-2-methylpropanamide Chemical compound C1=CC(NC(=O)C(C)(N)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MWLFQGAIUUZLMF-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- QFWBWWNWSWAQGO-UHFFFAOYSA-N 2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QFWBWWNWSWAQGO-UHFFFAOYSA-N 0.000 description 1
- KVPUKGOREHZUJO-UHFFFAOYSA-N 2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 KVPUKGOREHZUJO-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SGVJGELYUGOGCR-UHFFFAOYSA-N 3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 SGVJGELYUGOGCR-UHFFFAOYSA-N 0.000 description 1
- NZHHZQXOBAOWFS-UHFFFAOYSA-N 3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N(C)CCCN(C)C)=C1 NZHHZQXOBAOWFS-UHFFFAOYSA-N 0.000 description 1
- ZRMBBWINSMYQFN-UHFFFAOYSA-N 3-amino-1-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]propan-1-one Chemical compound NCCC(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 ZRMBBWINSMYQFN-UHFFFAOYSA-N 0.000 description 1
- AGJQWEILRRPDRV-UHFFFAOYSA-N 3-amino-1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)NC)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AGJQWEILRRPDRV-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- NLNNHKRHERFZND-UHFFFAOYSA-N 4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 NLNNHKRHERFZND-UHFFFAOYSA-N 0.000 description 1
- JOQLNQIDODVLEF-UHFFFAOYSA-N 4-[(9-methoxy-7-oxo-5,6-dihydropyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic acid Chemical compound C=1C(OC)=CC=C(C2=N3)C=1C(=O)NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 JOQLNQIDODVLEF-UHFFFAOYSA-N 0.000 description 1
- PEKHJJXBZMPALI-UHFFFAOYSA-N 4-[4-(3-aminopyrrolidine-1-carboximidoyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound NC1CN(CC1)C(C1=CC=C(C=C1)C1=NC(=NC2=C1CN=C(C1=C2C=CC(=C1)Cl)C1=C(C=CC=C1F)F)N)=N PEKHJJXBZMPALI-UHFFFAOYSA-N 0.000 description 1
- JXDVLJCKEXTWFW-UHFFFAOYSA-N 4-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methylpiperazine-2-carboxamide Chemical compound C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 JXDVLJCKEXTWFW-UHFFFAOYSA-N 0.000 description 1
- DLPLLXJMIXMJNT-UHFFFAOYSA-N 4-[[4-amino-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound N=1C(C2=CC=C(Cl)C=C2C(=NC2)C=3C(=CC=CC=3F)F)=C2C(N)=NC=1NC1=CC=C(C(O)=O)C=C1 DLPLLXJMIXMJNT-UHFFFAOYSA-N 0.000 description 1
- KOBUFCASZMLIHQ-UHFFFAOYSA-N 4-[[7-(2-bromo-6-chlorophenyl)-9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2Cl)Br)C3=N1 KOBUFCASZMLIHQ-UHFFFAOYSA-N 0.000 description 1
- BUALDNYOKKHJCF-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2C(=CC=CC=2)F)=C1 BUALDNYOKKHJCF-UHFFFAOYSA-N 0.000 description 1
- PSTMNQSMUJBCFU-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2C(=CC=CC=2)C)=C1 PSTMNQSMUJBCFU-UHFFFAOYSA-N 0.000 description 1
- OWEDUAXNWDZLQZ-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(furan-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2OC=CC=2)=C1 OWEDUAXNWDZLQZ-UHFFFAOYSA-N 0.000 description 1
- DKAHVJYKEGHJHO-UHFFFAOYSA-N 4-[[7-[2-(2-aminoethylamino)-6-fluorophenyl]-9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NCCN)C3=N1 DKAHVJYKEGHJHO-UHFFFAOYSA-N 0.000 description 1
- UQIPYZHWHXYKHL-UHFFFAOYSA-N 4-[[7-[2-(4-aminopiperidin-1-yl)-6-fluorophenyl]-9-chloro-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)N2CCC(N)CC2)C3=N1 UQIPYZHWHXYKHL-UHFFFAOYSA-N 0.000 description 1
- OSWRURQLZRZMQM-UHFFFAOYSA-N 4-[[9-bromo-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Br)C=2)C=2C(=CC=CC=2F)F)C3=N1 OSWRURQLZRZMQM-UHFFFAOYSA-N 0.000 description 1
- QVBSQDLYYDHSNV-UHFFFAOYSA-N 4-[[9-chloro-7-(2,3-difluorophenyl)-7h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(C=NC(C=2C(=C(F)C=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 QVBSQDLYYDHSNV-UHFFFAOYSA-N 0.000 description 1
- PTZKJRJFQZGPCI-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-dichlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2Cl)Cl)C3=N1 PTZKJRJFQZGPCI-UHFFFAOYSA-N 0.000 description 1
- NQDIAQSYIRAUHH-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5-methyl-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound N=1C=C2C(C)N=C(C=3C(=CC=CC=3F)F)C3=CC(Cl)=CC=C3C2=NC=1NC1=CC=C(C(O)=O)C=C1 NQDIAQSYIRAUHH-UHFFFAOYSA-N 0.000 description 1
- CCRLUFMMOYBDEU-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-N-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CCRLUFMMOYBDEU-UHFFFAOYSA-N 0.000 description 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
- MDCKGBAKEDQUNI-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 MDCKGBAKEDQUNI-UHFFFAOYSA-N 0.000 description 1
- BITVTLFNIDCPTC-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(C)CCN(C)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 BITVTLFNIDCPTC-UHFFFAOYSA-N 0.000 description 1
- PWXOHKPSRDYOKQ-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 PWXOHKPSRDYOKQ-UHFFFAOYSA-N 0.000 description 1
- FWLJKAPQUYTYTQ-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzonitrile Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C#N)C=C1 FWLJKAPQUYTYTQ-UHFFFAOYSA-N 0.000 description 1
- NKJSANVAPCGHJB-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-7h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(C=NC(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 NKJSANVAPCGHJB-UHFFFAOYSA-N 0.000 description 1
- UDSRUEBASZTLQC-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(O)cccc2F)ccc1C(O)=O UDSRUEBASZTLQC-UHFFFAOYSA-N 0.000 description 1
- BMOKTUMVDQVMHA-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2O)F)C3=N1 BMOKTUMVDQVMHA-UHFFFAOYSA-N 0.000 description 1
- FEMRNCIHZYHSSB-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCN(C)C)C=C1 FEMRNCIHZYHSSB-UHFFFAOYSA-N 0.000 description 1
- RDVBUVWXVRXLLC-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCCN(C)C)C=C1 RDVBUVWXVRXLLC-UHFFFAOYSA-N 0.000 description 1
- VRCFENKUBGJJHK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound CC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(O)=O)C=C1 VRCFENKUBGJJHK-UHFFFAOYSA-N 0.000 description 1
- CJKOMBCSMCOOLX-UHFFFAOYSA-N 4-[[9-chloro-7-(6-fluoro-6-methoxycyclohexa-2,4-dien-1-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound ClC1=CC2=C(C3=C(CN=C2C2C(C=CC=C2)(OC)F)C=NC(=N3)NC2=CC(=C(C(=O)O)C=C2)OC)C=C1 CJKOMBCSMCOOLX-UHFFFAOYSA-N 0.000 description 1
- PZLIVYQCUBSQGN-UHFFFAOYSA-N 4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C(F)(F)F)C=2C3=CC=C(Cl)C=2)C3=N1 PZLIVYQCUBSQGN-UHFFFAOYSA-N 0.000 description 1
- CXNWXQIOLUPIFA-UHFFFAOYSA-N 4-[[9-chloro-7-[2-[2-(dimethylamino)ethylamino]-6-fluorophenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NCCN(C)C)C3=N1 CXNWXQIOLUPIFA-UHFFFAOYSA-N 0.000 description 1
- CKIBXQMNSSOMLY-UHFFFAOYSA-N 4-[[9-chloro-7-[2-[4-(dimethylamino)piperidin-1-yl]-6-fluorophenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)N2CCC(CC2)N(C)C)C3=N1 CKIBXQMNSSOMLY-UHFFFAOYSA-N 0.000 description 1
- FOVOQGNRFWKHHP-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(2-hydroxyethylamino)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NCCO)C3=N1 FOVOQGNRFWKHHP-UHFFFAOYSA-N 0.000 description 1
- DVJZVJYCBPYPBM-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(methylamino)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)NC)C3=N1 DVJZVJYCBPYPBM-UHFFFAOYSA-N 0.000 description 1
- PTAZGIIWAMTJNC-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(trifluoromethoxy)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC(F)(F)F)=C1 PTAZGIIWAMTJNC-UHFFFAOYSA-N 0.000 description 1
- UCZOHMWZLSWKPI-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)C(F)(F)F)C3=N1 UCZOHMWZLSWKPI-UHFFFAOYSA-N 0.000 description 1
- YQCKGCMPPQNOEY-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-[methyl-[2-(methylamino)ethyl]amino]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound CNCCN(C)C1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC)C=C1 YQCKGCMPPQNOEY-UHFFFAOYSA-N 0.000 description 1
- FOGWFTNPUAVSCD-UHFFFAOYSA-N 4-[[9-chloro-7-[2-fluoro-6-[methyl-[3-(methylamino)propyl]amino]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound CNCCCN(C)C1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC)C=C1 FOGWFTNPUAVSCD-UHFFFAOYSA-N 0.000 description 1
- YGZJUOWPZSLWNV-UHFFFAOYSA-N 4-[[9-ethenyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 YGZJUOWPZSLWNV-UHFFFAOYSA-N 0.000 description 1
- NRJOLMQQQLDIPP-UHFFFAOYSA-N 4-[[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C#C)=C1 NRJOLMQQQLDIPP-UHFFFAOYSA-N 0.000 description 1
- HKHVPVKKKFXKQF-UHFFFAOYSA-N 4-amino-1-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n,n-dimethylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)N(C)C)(N)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HKHVPVKKKFXKQF-UHFFFAOYSA-N 0.000 description 1
- AHGMVDSJIDRREM-UHFFFAOYSA-N 4-amino-1-[2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)(N)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AHGMVDSJIDRREM-UHFFFAOYSA-N 0.000 description 1
- ZRZIZHAMCPSKNV-UHFFFAOYSA-N 4-amino-1-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)(N)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZRZIZHAMCPSKNV-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- SRLYKWYOXDIQDM-UHFFFAOYSA-N 4-n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-4-n-pyrimidin-2-ylbenzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1N(C=1N=C2C3=CC=C(Cl)C=C3C(=NCC2=CN=1)C=1C(=CC=CC=1F)F)C1=NC=CC=N1 SRLYKWYOXDIQDM-UHFFFAOYSA-N 0.000 description 1
- CFHCQZXHPXULBF-UHFFFAOYSA-N 4-n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CFHCQZXHPXULBF-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- JUIYNSILCQPBJT-UHFFFAOYSA-N 7-(2,6-difluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)C(O)=O)=C1 JUIYNSILCQPBJT-UHFFFAOYSA-N 0.000 description 1
- CRWGOWQOBLAJEH-UHFFFAOYSA-N 7-(2,6-difluorophenyl)-2-[4-(3,5-dimethylpiperazine-1-carbonyl)anilino]-n-methyl-5h-pyrimido[5,4-d][2]benzazepine-9-carboxamide Chemical compound C=1C(C(=O)NC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1F)F)=NCC2=CN=C3NC(C=C1)=CC=C1C(=O)N1CC(C)NC(C)C1 CRWGOWQOBLAJEH-UHFFFAOYSA-N 0.000 description 1
- YXFTUNPBIWOEAD-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxylic acid Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(O)=O)=C1 YXFTUNPBIWOEAD-UHFFFAOYSA-N 0.000 description 1
- WIFYBVWAADZGAA-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-(3-methoxyanilino)-n-(3-morpholin-4-ylpropyl)-5h-pyrimido[5,4-d][2]benzazepine-9-carboxamide Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(=O)NCCCN2CCOCC2)=C1 WIFYBVWAADZGAA-UHFFFAOYSA-N 0.000 description 1
- YJHSEAKWDKXWGP-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-(3-methoxyanilino)-n-methyl-n-[2-(methylamino)ethyl]-5h-pyrimido[5,4-d][2]benzazepine-9-carboxamide Chemical compound C=1C(C(=O)N(C)CCNC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)F)=NCC2=CN=C3NC1=CC=CC(OC)=C1 YJHSEAKWDKXWGP-UHFFFAOYSA-N 0.000 description 1
- KKOSUEPSCNZVOX-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-(3-methoxyanilino)-n-methyl-n-[3-(methylamino)propyl]-5h-pyrimido[5,4-d][2]benzazepine-9-carboxamide Chemical compound C=1C(C(=O)N(C)CCCNC)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)F)=NCC2=CN=C3NC1=CC=CC(OC)=C1 KKOSUEPSCNZVOX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YZAMGXFGCNKHRD-UHFFFAOYSA-N 9-bromo-7-(2,6-difluorophenyl)-n-(3-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(Br)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 YZAMGXFGCNKHRD-UHFFFAOYSA-N 0.000 description 1
- GTFVVWYYXBXPIG-UHFFFAOYSA-N 9-chloro-2-(3,4-dimethoxyanilino)-5,6-dihydropyrimido[5,4-d][2]benzazepin-7-one Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CNC(=O)C=2C3=CC=C(Cl)C=2)C3=N1 GTFVVWYYXBXPIG-UHFFFAOYSA-N 0.000 description 1
- ZJYARRRIOWFIBQ-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-(3-iodophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(I)=C1 ZJYARRRIOWFIBQ-UHFFFAOYSA-N 0.000 description 1
- NXFRTLPEWJLCNZ-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-(4-nitrophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 NXFRTLPEWJLCNZ-UHFFFAOYSA-N 0.000 description 1
- YIKFBKOBWIWMFZ-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-(5-methyl-1h-pyrazol-3-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound N1N=C(C)C=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 YIKFBKOBWIWMFZ-UHFFFAOYSA-N 0.000 description 1
- VOYXSUZPNLKNPN-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[2-(methylaminomethyl)-3h-benzimidazol-5-yl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F VOYXSUZPNLKNPN-UHFFFAOYSA-N 0.000 description 1
- HSRQBJXYTYQIQH-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[3-(2,2,6,6-tetramethylpiperidin-4-yl)oxyphenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(C)(C)NC(C)(C)CC1OC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 HSRQBJXYTYQIQH-UHFFFAOYSA-N 0.000 description 1
- OVMCGKSXHJMTKO-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[3-(3,5-dimethylpiperazine-1-carboximidoyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(C)NC(C)CN1C(=N)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 OVMCGKSXHJMTKO-UHFFFAOYSA-N 0.000 description 1
- CQDNUGURIHTGBD-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[3-[3-(dimethylamino)propyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound CN(C)CCCC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 CQDNUGURIHTGBD-UHFFFAOYSA-N 0.000 description 1
- JCKBNPHSNXGTGQ-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-(3,5-dimethylpiperazine-1-carboximidoyl)-3-fluorophenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(C)NC(C)CN1C(=N)C(C(=C1)F)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 JCKBNPHSNXGTGQ-UHFFFAOYSA-N 0.000 description 1
- AKDKGEOUADXKBO-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-(3,5-dimethylpiperazine-1-carboximidoyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(C)NC(C)CN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AKDKGEOUADXKBO-UHFFFAOYSA-N 0.000 description 1
- XKHWJBZPHITCMS-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-(5,5-dimethyl-1,4-dihydroimidazol-2-yl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound N1C(C)(C)CN=C1C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 XKHWJBZPHITCMS-UHFFFAOYSA-N 0.000 description 1
- QIYQPPYNEXEYGT-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[3-(dimethylamino)azetidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(N(C)C)CN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QIYQPPYNEXEYGT-UHFFFAOYSA-N 0.000 description 1
- MVKQXBBJRQOBJV-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[3-(dimethylamino)pyrrolidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(N(C)C)CCN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MVKQXBBJRQOBJV-UHFFFAOYSA-N 0.000 description 1
- FWOGTUIEZYZYED-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[3-(methylamino)pyrrolidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1C(NC)CCN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 FWOGTUIEZYZYED-UHFFFAOYSA-N 0.000 description 1
- AVDMAQJRJPBQAI-UHFFFAOYSA-N 9-chloro-7-(2,6-difluorophenyl)-n-[4-[4-(dimethylamino)piperidine-1-carboximidoyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1CC(N(C)C)CCN1C(=N)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AVDMAQJRJPBQAI-UHFFFAOYSA-N 0.000 description 1
- QVPBYYVGOOTSBG-UHFFFAOYSA-N 9-chloro-7-(2-fluorophenyl)-n-[2-(methylaminomethyl)-3h-benzimidazol-5-yl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F QVPBYYVGOOTSBG-UHFFFAOYSA-N 0.000 description 1
- CKEPAAVNYCQCDF-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 CKEPAAVNYCQCDF-UHFFFAOYSA-N 0.000 description 1
- YADXMNGUVRGUTB-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-(2-fluorophenyl)-6,7-dihydro-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CNC(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 YADXMNGUVRGUTB-UHFFFAOYSA-N 0.000 description 1
- CTMQQWLPOQFGGR-UHFFFAOYSA-N 9-chloro-n-(3,4-dimethoxyphenyl)-7-[2-[(dimethylamino)methyl]phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)CN(C)C)C=2C3=CC=C(Cl)C=2)C3=N1 CTMQQWLPOQFGGR-UHFFFAOYSA-N 0.000 description 1
- LXFHDCCVRHNYCZ-UHFFFAOYSA-N 9-chloro-n-[2-[(dimethylamino)methyl]-3h-benzimidazol-5-yl]-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CN(C)C)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F LXFHDCCVRHNYCZ-UHFFFAOYSA-N 0.000 description 1
- IRHNNUSKDHCDIX-UHFFFAOYSA-N 9-chloro-n-[4-(2,6-dimethylpiperidin-4-yl)phenyl]-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C2CC(C)NC(C)C2)C=C1 IRHNNUSKDHCDIX-UHFFFAOYSA-N 0.000 description 1
- FYDNJAGBGXLZJU-UHFFFAOYSA-N 9-methoxy-2-[4-[3-(methylamino)pyrrolidine-1-carbonyl]anilino]-5,6-dihydropyrimido[5,4-d][2]benzazepin-7-one Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CNC(=O)C=2C3=CC=C(OC)C=2)C3=N1 FYDNJAGBGXLZJU-UHFFFAOYSA-N 0.000 description 1
- 101150056293 AJUBA gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241001236093 Bulbophyllum maximum Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BQNHAOZWMNDAFY-UHFFFAOYSA-N C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C2=C3C4=CC=CC=C4O2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C2=C3C4=CC=CC=C4O2)C=2C(=CC=CC=2F)F)C3=N1 BQNHAOZWMNDAFY-UHFFFAOYSA-N 0.000 description 1
- BDDAPWWRCPGMSB-UHFFFAOYSA-N C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3OC=C2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3OC=C2)C=2C(=CC=CC=2F)F)C3=N1 BDDAPWWRCPGMSB-UHFFFAOYSA-N 0.000 description 1
- UAPYMMAOYLNGRA-UHFFFAOYSA-N C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3ON=C2)C=2C(=CC=CC=2F)F)C3=N1 Chemical compound C1CNC(C(=O)NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C2=C3ON=C2)C=2C(=CC=CC=2F)F)C3=N1 UAPYMMAOYLNGRA-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- UOIDECOHFXDHKT-UHFFFAOYSA-N C=1C=C2C(C)=NNC2=CC=1NC(N=C1C2=C3C4=CC=CC=C4N2)=NC=C1CN=C3C1=CC=CC=C1F Chemical compound C=1C=C2C(C)=NNC2=CC=1NC(N=C1C2=C3C4=CC=CC=C4N2)=NC=C1CN=C3C1=CC=CC=C1F UOIDECOHFXDHKT-UHFFFAOYSA-N 0.000 description 1
- YCVKEOMQSDTQPF-UHFFFAOYSA-N CC(N)(C)C(=O)N(C)C1=CC=CC(NC=2N=C3C4=C(C)SC(C)=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 Chemical compound CC(N)(C)C(=O)N(C)C1=CC=CC(NC=2N=C3C4=C(C)SC(C)=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 YCVKEOMQSDTQPF-UHFFFAOYSA-N 0.000 description 1
- BYWYLFDDCCJZIC-UHFFFAOYSA-N CN1C=CC(C2=N3)=C1C(=O)NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 Chemical compound CN1C=CC(C2=N3)=C1C(=O)NCC2=CN=C3NC1=CC=C(C(O)=O)C=C1 BYWYLFDDCCJZIC-UHFFFAOYSA-N 0.000 description 1
- AUCGPCQXKQQBOP-UHFFFAOYSA-N CN1N=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 Chemical compound CN1N=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 AUCGPCQXKQQBOP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108010076303 Centromere Protein A Proteins 0.000 description 1
- 102000011682 Centromere Protein A Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101001124881 Cricetulus griseus Peroxiredoxin-1 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- QRODIWRVFWQZMZ-UHFFFAOYSA-N FC1=CC=CC=C1C1=NC(NC=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2OC=CC=2)=NC2=C1CN=CC1=CC=CC=C21 Chemical compound FC1=CC=CC=C1C1=NC(NC=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2OC=CC=2)=NC2=C1CN=CC1=CC=CC=C21 QRODIWRVFWQZMZ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000960484 Homo sapiens Inner centromere protein Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100039872 Inner centromere protein Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101000864132 Mus musculus Dipeptidase 3 Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102000005640 Myosin Type II Human genes 0.000 description 1
- 108010045128 Myosin Type II Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- TYBCSQFBSWACAA-UHFFFAOYSA-N Nonan-4-one Chemical compound CCCCCC(=O)CCC TYBCSQFBSWACAA-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 101710196218 Rac GTPase-activating protein 1 Proteins 0.000 description 1
- 102100037414 Rac GTPase-activating protein 1 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- AHIMOUYSCBWMGQ-UHFFFAOYSA-N S1C(C)=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 Chemical compound S1C(C)=CC(C(=NCC2=CN=3)C=4C(=CC=CC=4F)F)=C1C2=NC=3NC1=CC=C(C(O)=O)C=C1 AHIMOUYSCBWMGQ-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 201000011648 T-cell childhood lymphoblastic lymphoma Diseases 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 201000000170 Thyroid lymphoma Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 231100000480 WST assay Toxicity 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- OXVJTPVQRUVXBF-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-oxazol-4-yl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=COC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 OXVJTPVQRUVXBF-UHFFFAOYSA-N 0.000 description 1
- XHEHCHPUTNDMNH-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-oxazol-4-yl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C1=COC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 XHEHCHPUTNDMNH-UHFFFAOYSA-N 0.000 description 1
- STSSTKKIDXHRDW-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-oxazol-5-yl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(O1)=CN=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 STSSTKKIDXHRDW-UHFFFAOYSA-N 0.000 description 1
- GUKHLEIFWXAXDX-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-thiazol-4-yl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 GUKHLEIFWXAXDX-UHFFFAOYSA-N 0.000 description 1
- MMWWLLXGJODWDC-CQSZACIVSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-thiazol-4-yl]-[(3r)-3-methylpiperazin-1-yl]methanone Chemical compound C1CN[C@H](C)CN1C(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 MMWWLLXGJODWDC-CQSZACIVSA-N 0.000 description 1
- DSDKJHOPQBYWOM-UHFFFAOYSA-N [2-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-1,3-thiazol-4-yl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 DSDKJHOPQBYWOM-UHFFFAOYSA-N 0.000 description 1
- ZUFGUHAPXIWEFW-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound C1CNC(C)CN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZUFGUHAPXIWEFW-UHFFFAOYSA-N 0.000 description 1
- JWDPUKOTDVYYJT-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 JWDPUKOTDVYYJT-UHFFFAOYSA-N 0.000 description 1
- DJEDXBLNBAIGES-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1CC(N(C)C)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DJEDXBLNBAIGES-UHFFFAOYSA-N 0.000 description 1
- WIZVBPSFRAEIQX-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 WIZVBPSFRAEIQX-UHFFFAOYSA-N 0.000 description 1
- SFVRQKXBKPAICR-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-methyl-4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)(C)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 SFVRQKXBKPAICR-UHFFFAOYSA-N 0.000 description 1
- GPSASWQGSYFFDU-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,3,5,5-tetramethylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC(C=C1Cl)=CC=C1C(=O)N1CC(C)(C)NC(C)(C)C1 GPSASWQGSYFFDU-UHFFFAOYSA-N 0.000 description 1
- DTWXJOMXKCKQQH-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-methyl-3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)(C)CCCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 DTWXJOMXKCKQQH-UHFFFAOYSA-N 0.000 description 1
- UNHNHMLAEUUYIA-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 UNHNHMLAEUUYIA-UHFFFAOYSA-N 0.000 description 1
- ZDKMDXHVXGDYSL-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound C1CNC(C)CN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 ZDKMDXHVXGDYSL-UHFFFAOYSA-N 0.000 description 1
- NQFPMOULASDERT-UHFFFAOYSA-N [2-chloro-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC(C=C1Cl)=CC=C1C(=O)N1CCN(CCN2CCCC2)CC1 NQFPMOULASDERT-UHFFFAOYSA-N 0.000 description 1
- WOYLUGMXNZTSFS-UHFFFAOYSA-N [2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1Cl WOYLUGMXNZTSFS-UHFFFAOYSA-N 0.000 description 1
- PILCNIDUGHFEFS-UHFFFAOYSA-N [2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1Cl PILCNIDUGHFEFS-UHFFFAOYSA-N 0.000 description 1
- JKJFLXAHLGSTTN-UHFFFAOYSA-N [2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1CC(N(C)C)CCN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1Cl JKJFLXAHLGSTTN-UHFFFAOYSA-N 0.000 description 1
- SMCFNGLZHYJRKU-UHFFFAOYSA-N [2-chloro-5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1Cl SMCFNGLZHYJRKU-UHFFFAOYSA-N 0.000 description 1
- RDKPHXFXZHAQON-UHFFFAOYSA-N [3-(aminomethyl)azetidin-1-yl]-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound C1C(CN)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 RDKPHXFXZHAQON-UHFFFAOYSA-N 0.000 description 1
- RFHIDHFLYPPTHW-UHFFFAOYSA-N [3-(dimethylamino)azetidin-1-yl]-[7-(2-fluorophenyl)-2-(3-methoxyanilino)-5h-pyrimido[5,4-d][2]benzazepin-9-yl]methanone Chemical compound COC1=CC=CC(NC=2N=C3C4=CC=C(C=C4C(C=4C(=CC=CC=4)F)=NCC3=CN=2)C(=O)N2CC(C2)N(C)C)=C1 RFHIDHFLYPPTHW-UHFFFAOYSA-N 0.000 description 1
- VOCBMCLMCJWHJP-UHFFFAOYSA-N [3-(dimethylamino)pyrrolidin-1-yl]-[4-[[7-(2-fluorophenyl)-9-methoxy-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanone Chemical compound N=1C=C2CN=C(C=3C(=CC=CC=3)F)C3=CC(OC)=CC=C3C2=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(N(C)C)C1 VOCBMCLMCJWHJP-UHFFFAOYSA-N 0.000 description 1
- FPWKWLRIMBPMPP-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 FPWKWLRIMBPMPP-UHFFFAOYSA-N 0.000 description 1
- QCSIIGVRKKZRNQ-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound C1C(N(C)C)CN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 QCSIIGVRKKZRNQ-UHFFFAOYSA-N 0.000 description 1
- AZULRYAVQSYDEE-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 AZULRYAVQSYDEE-UHFFFAOYSA-N 0.000 description 1
- SVYOHTBHNSKSEB-UHFFFAOYSA-N [3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1CC(N(C)C)CCN1C(=O)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 SVYOHTBHNSKSEB-UHFFFAOYSA-N 0.000 description 1
- CFPCXOXZWZIHLB-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CC(C)NC(C)C2)=C1 CFPCXOXZWZIHLB-UHFFFAOYSA-N 0.000 description 1
- WJHWFOPIRQIOKP-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CCN(C)CC2)=C1 WJHWFOPIRQIOKP-UHFFFAOYSA-N 0.000 description 1
- LCOQJGSBZMGDGI-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CC(C2)N(C)C)=C1 LCOQJGSBZMGDGI-UHFFFAOYSA-N 0.000 description 1
- NYIODPTWPANCLJ-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CC(CC2)N(C)C)=C1 NYIODPTWPANCLJ-UHFFFAOYSA-N 0.000 description 1
- JPFVLUUDWMCCAG-UHFFFAOYSA-N [3-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=CC(C(=O)N2CCC(CC2)N(C)C)=C1 JPFVLUUDWMCCAG-UHFFFAOYSA-N 0.000 description 1
- HFKBMAQAJZRFIP-UHFFFAOYSA-N [4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 HFKBMAQAJZRFIP-UHFFFAOYSA-N 0.000 description 1
- UOEWNLVURFTZMF-UHFFFAOYSA-N [4-[(9-chloro-7-pyridin-2-yl-5h-pyrimido[5,4-d][2]benzazepin-2-yl)amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2N=CC=CC=2)C=2C3=CC=C(Cl)C=2)C3=N1 UOEWNLVURFTZMF-UHFFFAOYSA-N 0.000 description 1
- UEOKIKQGOFBIMC-UHFFFAOYSA-N [4-[[9-chloro-7-(2,4-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC(F)=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 UEOKIKQGOFBIMC-UHFFFAOYSA-N 0.000 description 1
- NTQDMLHWEVSKEX-UHFFFAOYSA-N [4-[[9-chloro-7-(2,4-dimethoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-2-yl)methanone Chemical compound COC1=CC(OC)=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)C2C(NC(C)CN2)C)C=C1 NTQDMLHWEVSKEX-UHFFFAOYSA-N 0.000 description 1
- DRCDQFVPGQYTGE-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C(=C1)F)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 DRCDQFVPGQYTGE-UHFFFAOYSA-N 0.000 description 1
- RKGRLMWQUSSEKX-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(1,7-diazaspiro[4.4]nonan-7-yl)methanone Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC3(NCCC3)CC2)C=C1 RKGRLMWQUSSEKX-UHFFFAOYSA-N 0.000 description 1
- CNTXXRJMWPIXTO-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,3,5-trimethylpiperazin-1-yl)methanone Chemical compound C1C(C)(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 CNTXXRJMWPIXTO-UHFFFAOYSA-N 0.000 description 1
- JWWDPRNGKZVUMX-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,3-dimethylpiperazin-1-yl)methanone Chemical compound C1CNC(C)(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 JWWDPRNGKZVUMX-UHFFFAOYSA-N 0.000 description 1
- KYQZHCBVZKULNV-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 KYQZHCBVZKULNV-UHFFFAOYSA-N 0.000 description 1
- VJCKVVTYEDVBED-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,8-diazabicyclo[3.2.1]octan-3-yl)methanone Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC3CCC(N3)C2)C=C1 VJCKVVTYEDVBED-UHFFFAOYSA-N 0.000 description 1
- IVGJRVQOUHYMLJ-QGZVFWFLSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[(2r)-2-methylpiperazin-1-yl]methanone Chemical compound C[C@@H]1CNCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 IVGJRVQOUHYMLJ-QGZVFWFLSA-N 0.000 description 1
- UENJLDMULQEBHP-QGZVFWFLSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[(3r)-3-methylpiperazin-1-yl]methanone Chemical compound C1CN[C@H](C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 UENJLDMULQEBHP-QGZVFWFLSA-N 0.000 description 1
- UENJLDMULQEBHP-KRWDZBQOSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[(3s)-3-methylpiperazin-1-yl]methanone Chemical compound C1CN[C@@H](C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 UENJLDMULQEBHP-KRWDZBQOSA-N 0.000 description 1
- STJRCYQMHYOAMU-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)-3-methylpyrrolidin-1-yl]methanone Chemical compound C1C(N(C)C)(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 STJRCYQMHYOAMU-UHFFFAOYSA-N 0.000 description 1
- WGEPKVSOIXBWQW-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound C1C(N(C)C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 WGEPKVSOIXBWQW-UHFFFAOYSA-N 0.000 description 1
- MGSGOFCZEMKUCR-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1C(N(C)C)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MGSGOFCZEMKUCR-UHFFFAOYSA-N 0.000 description 1
- MEIGAGMDRBJICH-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MEIGAGMDRBJICH-UHFFFAOYSA-N 0.000 description 1
- MFIVRJWZUDNKPE-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)-7-azabicyclo[2.2.1]heptan-7-yl]methanone Chemical compound CNC1CC2CCC1N2C(=O)C(C=C1)=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F MFIVRJWZUDNKPE-UHFFFAOYSA-N 0.000 description 1
- ABHIUWCULMTVEH-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)-8-azabicyclo[3.2.1]octan-8-yl]methanone Chemical compound C1C(NC)CC2CCC1N2C(=O)C(C=C1)=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F ABHIUWCULMTVEH-UHFFFAOYSA-N 0.000 description 1
- SCRPSVZKDSAKPL-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 SCRPSVZKDSAKPL-UHFFFAOYSA-N 0.000 description 1
- GYSKVJHJGKIETN-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 GYSKVJHJGKIETN-UHFFFAOYSA-N 0.000 description 1
- WIPLXBYUWHBYNE-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-methyl-3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)(C)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 WIPLXBYUWHBYNE-UHFFFAOYSA-N 0.000 description 1
- VOEILCGYYKEQQU-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-methyl-3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 VOEILCGYYKEQQU-UHFFFAOYSA-N 0.000 description 1
- RLEKDRSCNZHLAK-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)-4-methylpiperidin-1-yl]methanone Chemical compound C1CC(N(C)C)(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 RLEKDRSCNZHLAK-UHFFFAOYSA-N 0.000 description 1
- GMGDXUNAZFDGOM-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 GMGDXUNAZFDGOM-UHFFFAOYSA-N 0.000 description 1
- QWJSOMWZNWRRJK-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-methyl-4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QWJSOMWZNWRRJK-UHFFFAOYSA-N 0.000 description 1
- ZSVJENQHRNFUIP-UHFFFAOYSA-N [4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCNCC2)C=C1 ZSVJENQHRNFUIP-UHFFFAOYSA-N 0.000 description 1
- ZCAIBCLXMDOENG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 ZCAIBCLXMDOENG-UHFFFAOYSA-N 0.000 description 1
- FNZFUKLUWKTHFW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 FNZFUKLUWKTHFW-UHFFFAOYSA-N 0.000 description 1
- MLTMXRTWNAKQMG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 MLTMXRTWNAKQMG-UHFFFAOYSA-N 0.000 description 1
- FLXROWSQTLOAJX-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 FLXROWSQTLOAJX-UHFFFAOYSA-N 0.000 description 1
- AQAXYAXPHYNCFW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chloro-6-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)Cl)C3=N1 AQAXYAXPHYNCFW-UHFFFAOYSA-N 0.000 description 1
- GQZMHHNJASLKHG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-chlorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-morpholin-4-ylmethanone Chemical compound C=1C(Cl)=CC=C(C2=N3)C=1C(C=1C(=CC=CC=1)Cl)=NCC2=CN=C3NC(C=C1)=CC=C1C(=O)N1CCOCC1 GQZMHHNJASLKHG-UHFFFAOYSA-N 0.000 description 1
- XRMDEOCOIDQTPA-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-[4-methyl-4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)(C)CCN1C(=O)C(C(=C1)F)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 XRMDEOCOIDQTPA-UHFFFAOYSA-N 0.000 description 1
- QQSWJLPPKVFTKY-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NC(C)C2)C=C1 QQSWJLPPKVFTKY-UHFFFAOYSA-N 0.000 description 1
- QVMLEHCETZHYGS-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NCC2)C=C1 QVMLEHCETZHYGS-UHFFFAOYSA-N 0.000 description 1
- LRYDYNYVXSTZRZ-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(C)CC2)C=C1 LRYDYNYVXSTZRZ-UHFFFAOYSA-N 0.000 description 1
- AKUXUDHJYZZIQE-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)azetidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C2)N(C)C)C=C1 AKUXUDHJYZZIQE-UHFFFAOYSA-N 0.000 description 1
- GNMZSSZQDIVGRS-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(CC2)N(C)C)C=C1 GNMZSSZQDIVGRS-UHFFFAOYSA-N 0.000 description 1
- SJUVKSPWBNXCEP-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)-8-azabicyclo[3.2.1]octan-8-yl]methanone Chemical compound C1C(NC)CC2CCC1N2C(=O)C(C=C1)=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1OC SJUVKSPWBNXCEP-UHFFFAOYSA-N 0.000 description 1
- MNCFMJGFDNSRHG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 MNCFMJGFDNSRHG-UHFFFAOYSA-N 0.000 description 1
- FESBJMYHIBQZSK-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 FESBJMYHIBQZSK-UHFFFAOYSA-N 0.000 description 1
- WOBYARIWHITLKA-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 WOBYARIWHITLKA-UHFFFAOYSA-N 0.000 description 1
- VQHITOKEIOZARG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-methyl-3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)(C)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 VQHITOKEIOZARG-UHFFFAOYSA-N 0.000 description 1
- RBEOXDBUQQBFFJ-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCC(CC2)N(C)C)C=C1 RBEOXDBUQQBFFJ-UHFFFAOYSA-N 0.000 description 1
- JFVGHUIGWMJZSE-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 JFVGHUIGWMJZSE-UHFFFAOYSA-N 0.000 description 1
- NUSGQSHJBFWKJD-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-methyl-4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)OC)C3=N1 NUSGQSHJBFWKJD-UHFFFAOYSA-N 0.000 description 1
- VMAWGROBIQSXOO-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCNCC2)C=C1 VMAWGROBIQSXOO-UHFFFAOYSA-N 0.000 description 1
- JSVWQMNITPGROU-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(2-methylpiperazin-1-yl)methanone Chemical compound CC1CNCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 JSVWQMNITPGROU-UHFFFAOYSA-N 0.000 description 1
- NFUMINIKCHIFEY-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CC2)C=2N=CC=CC=2)C=C1 NFUMINIKCHIFEY-UHFFFAOYSA-N 0.000 description 1
- PALAFUUAIJDZQG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-pyrimidin-2-ylpiperazin-1-yl)methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CC2)C=2N=CC=CN=2)C=C1 PALAFUUAIJDZQG-UHFFFAOYSA-N 0.000 description 1
- KUZNSVLBLFXAAI-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(2-ethoxyphenyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC=CC=C1N1CCN(C(=O)C=2C=CC(NC=3N=C4C5=CC=C(Cl)C=C5C(C=5C(=CC=CC=5)F)=NCC4=CN=3)=CC=2)CC1 KUZNSVLBLFXAAI-UHFFFAOYSA-N 0.000 description 1
- NWRJTHXGRBWZJV-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CCN3CCOCC3)CC2)C=C1 NWRJTHXGRBWZJV-UHFFFAOYSA-N 0.000 description 1
- XEVOAZSKPSFYTB-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(2-piperidin-1-ylethyl)piperazin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CCN3CCCCC3)CC2)C=C1 XEVOAZSKPSFYTB-UHFFFAOYSA-N 0.000 description 1
- ZZZJQNBDPXRRMA-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CCN3CCCC3)CC2)C=C1 ZZZJQNBDPXRRMA-UHFFFAOYSA-N 0.000 description 1
- DKABBLLBJKNWNW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(3-piperidin-1-ylpropyl)piperazin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CCCN3CCCCC3)CC2)C=C1 DKABBLLBJKNWNW-UHFFFAOYSA-N 0.000 description 1
- PQKZJOHXJGJKCV-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(3-pyrrolidin-1-ylpropyl)piperazin-1-yl]methanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCN(CCCN3CCCC3)CC2)C=C1 PQKZJOHXJGJKCV-UHFFFAOYSA-N 0.000 description 1
- JYKXGFCMYODZSU-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-[(1-methylpiperidin-3-yl)methyl]piperazin-1-yl]methanone Chemical compound C1N(C)CCCC1CN1CCN(C(=O)C=2C=CC(NC=3N=C4C5=CC=C(Cl)C=C5C(C=5C(=CC=CC=5)F)=NCC4=CN=3)=CC=2)CC1 JYKXGFCMYODZSU-UHFFFAOYSA-N 0.000 description 1
- DQWGQWPZOJWPON-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-[2-(diethylamino)ethyl]piperazin-1-yl]methanone Chemical compound C1CN(CCN(CC)CC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 DQWGQWPZOJWPON-UHFFFAOYSA-N 0.000 description 1
- KYMPYXCKWRVANW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-[2-(dipropylamino)ethyl]piperazin-1-yl]methanone Chemical compound C1CN(CCN(CCC)CCC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 KYMPYXCKWRVANW-UHFFFAOYSA-N 0.000 description 1
- HEWDDRCGZXRKOU-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-[3-(diethylamino)propyl]piperazin-1-yl]methanone Chemical compound C1CN(CCCN(CC)CC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 HEWDDRCGZXRKOU-UHFFFAOYSA-N 0.000 description 1
- LAZJVOYDBZAPCT-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-[3-(dimethylamino)propyl]piperazin-1-yl]methanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 LAZJVOYDBZAPCT-UHFFFAOYSA-N 0.000 description 1
- CRONKPYVVQHUSG-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-morpholin-4-ylmethanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCOCC2)C=C1 CRONKPYVVQHUSG-UHFFFAOYSA-N 0.000 description 1
- KKJRAJNOPIWLOK-UHFFFAOYSA-N [4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-piperazin-1-ylmethanone Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CCNCC2)C=C1 KKJRAJNOPIWLOK-UHFFFAOYSA-N 0.000 description 1
- CEIKCVXEVNUPHX-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NC(C)C2)C=C1 CEIKCVXEVNUPHX-UHFFFAOYSA-N 0.000 description 1
- YFILSMVPEUGYQH-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(3-methylpiperazin-1-yl)methanone Chemical compound COC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N2CC(C)NCC2)C=C1 YFILSMVPEUGYQH-UHFFFAOYSA-N 0.000 description 1
- ZNZWMZUHXSNPES-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)piperidin-1-yl]methanone Chemical compound C1C(NC)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)OC)C=2C3=CC=C(Cl)C=2)C3=N1 ZNZWMZUHXSNPES-UHFFFAOYSA-N 0.000 description 1
- FMQYOABKPQSROW-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)OC)C=2C3=CC=C(Cl)C=2)C3=N1 FMQYOABKPQSROW-UHFFFAOYSA-N 0.000 description 1
- SAJIRGBREXTLIH-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)OC)C=2C3=CC=C(Cl)C=2)C3=N1 SAJIRGBREXTLIH-UHFFFAOYSA-N 0.000 description 1
- DQNYWRYOKXUOAO-UHFFFAOYSA-N [4-[[9-chloro-7-(2-methylphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)C)C=2C3=CC=C(Cl)C=2)C3=N1 DQNYWRYOKXUOAO-UHFFFAOYSA-N 0.000 description 1
- NZSVWAIAMHAHMK-UHFFFAOYSA-N [4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone Chemical compound C1C(NC)CN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 NZSVWAIAMHAHMK-UHFFFAOYSA-N 0.000 description 1
- PUAPYPFCEDXFAQ-UHFFFAOYSA-N [4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[3-(methylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 PUAPYPFCEDXFAQ-UHFFFAOYSA-N 0.000 description 1
- MXGAEISYBDKLSD-UHFFFAOYSA-N [4-[[9-chloro-7-[2-(trifluoromethyl)phenyl]-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-[4-(methylamino)piperidin-1-yl]methanone Chemical compound C1CC(NC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2)C(F)(F)F)C3=N1 MXGAEISYBDKLSD-UHFFFAOYSA-N 0.000 description 1
- GDQCFWNDQNGBGL-UHFFFAOYSA-N [5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1F GDQCFWNDQNGBGL-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- PRFSSNFDGRXIPZ-UHFFFAOYSA-N amino 4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)ON)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 PRFSSNFDGRXIPZ-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical compound O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000005770 chromosome separation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- MKARNSWMMBGSHX-UHFFFAOYSA-N m-xylylamine Natural products CC1=CC(C)=CC(N)=C1 MKARNSWMMBGSHX-UHFFFAOYSA-N 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000036456 mitotic arrest Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QKUFDQABZMVAGS-UHFFFAOYSA-N n'-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-3,5-dimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(N)=NC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 QKUFDQABZMVAGS-UHFFFAOYSA-N 0.000 description 1
- MFXOKBSYLJVJCL-UHFFFAOYSA-N n'-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-3,5-dimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)NC(C(=C1)F)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 MFXOKBSYLJVJCL-UHFFFAOYSA-N 0.000 description 1
- QVNJSNBFEUZNSN-UHFFFAOYSA-N n'-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-3,5-dimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)NC(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 QVNJSNBFEUZNSN-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
- AVAWMINJNRAQFS-UHFFFAOYSA-N n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)C1CCNC1 AVAWMINJNRAQFS-UHFFFAOYSA-N 0.000 description 1
- UOKNHTIHWYPJKN-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)C2C3CCN(CC3)C2)C=C1 UOKNHTIHWYPJKN-UHFFFAOYSA-N 0.000 description 1
- LEJCCDWWRZHAMO-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound FC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=NC2=CC=CC=C2N1 LEJCCDWWRZHAMO-UHFFFAOYSA-N 0.000 description 1
- VWWHOZYCTHVRRF-UHFFFAOYSA-N n-(2-aminoethyl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(CCN)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 VWWHOZYCTHVRRF-UHFFFAOYSA-N 0.000 description 1
- GYXVPOGEOJOMKM-UHFFFAOYSA-N n-(2-aminoethyl)-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCN)C=C1 GYXVPOGEOJOMKM-UHFFFAOYSA-N 0.000 description 1
- ZJBHAWQXDCSKLI-UHFFFAOYSA-N n-(3-aminopropyl)-4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)N(CCCN)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 ZJBHAWQXDCSKLI-UHFFFAOYSA-N 0.000 description 1
- KJHREAWVRQOONJ-UHFFFAOYSA-N n-(3-aminopropyl)-4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-n-methylbenzamide Chemical compound COC1=CC=CC(F)=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)N(C)CCCN)C=C1 KJHREAWVRQOONJ-UHFFFAOYSA-N 0.000 description 1
- ZGXSVPBBJWYHTJ-UHFFFAOYSA-N n-[2-(aminomethyl)-3h-benzimidazol-5-yl]-9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=C2NC(CN)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F ZGXSVPBBJWYHTJ-UHFFFAOYSA-N 0.000 description 1
- BQWPHMFMLAYMSG-UHFFFAOYSA-N n-[3-(3-aminopropyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound NCCCC1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 BQWPHMFMLAYMSG-UHFFFAOYSA-N 0.000 description 1
- LJPBXJHIGJTHMR-UHFFFAOYSA-N n-[3-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n,3,5-trimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)N(C)C1=CC=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=C1 LJPBXJHIGJTHMR-UHFFFAOYSA-N 0.000 description 1
- HNYZCNTVOLHSBC-UHFFFAOYSA-N n-[4-(2-aminopropan-2-yl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-amine Chemical compound C1=CC(C(C)(N)C)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HNYZCNTVOLHSBC-UHFFFAOYSA-N 0.000 description 1
- RYWAVKNACUAFFX-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)NC(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 RYWAVKNACUAFFX-UHFFFAOYSA-N 0.000 description 1
- AJNXOMNOGKUFRX-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n,3,5-trimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)N(C)C(C=C1)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 AJNXOMNOGKUFRX-UHFFFAOYSA-N 0.000 description 1
- ZUGMRLYZBBKMBV-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 ZUGMRLYZBBKMBV-UHFFFAOYSA-N 0.000 description 1
- XHRROFJZSNGMIU-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 XHRROFJZSNGMIU-UHFFFAOYSA-N 0.000 description 1
- HZRKQUYYBNRBOG-UHFFFAOYSA-N n-[4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1NC1=NC=C(CN=C(C=2C(=CC=CC=2)F)C=2C3=CC=C(Cl)C=2)C3=N1 HZRKQUYYBNRBOG-UHFFFAOYSA-N 0.000 description 1
- QXRQEGYLMFFLTJ-UHFFFAOYSA-N n-[5-[[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-fluorophenyl]-n,3,5-trimethylpiperazine-1-carboximidamide Chemical compound C1C(C)NC(C)CN1C(=N)N(C)C1=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=CC=C1F QXRQEGYLMFFLTJ-UHFFFAOYSA-N 0.000 description 1
- LWLRBBDMNHLNMT-UHFFFAOYSA-N n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzothiazol-6-amine Chemical compound C1=C2SC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F LWLRBBDMNHLNMT-UHFFFAOYSA-N 0.000 description 1
- YXQFSBBYATXRJN-UHFFFAOYSA-N n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzoxazol-6-amine Chemical compound C1=C2OC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=C(F)C=CC=C1F YXQFSBBYATXRJN-UHFFFAOYSA-N 0.000 description 1
- AFNYBWFXRSXFKZ-UHFFFAOYSA-N n-[9-chloro-7-(2,6-difluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)F)=N1 AFNYBWFXRSXFKZ-UHFFFAOYSA-N 0.000 description 1
- CQYDWYWXUWKLQS-UHFFFAOYSA-N n-[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzothiazol-6-amine Chemical compound C1=C2SC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F CQYDWYWXUWKLQS-UHFFFAOYSA-N 0.000 description 1
- RDPVZBDRLHROEM-UHFFFAOYSA-N n-[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]-2-(methylaminomethyl)-1,3-benzoxazol-6-amine Chemical compound C1=C2OC(CNC)=NC2=CC=C1NC(N=C1C2=CC=C(Cl)C=C22)=NC=C1CN=C2C1=CC=CC=C1F RDPVZBDRLHROEM-UHFFFAOYSA-N 0.000 description 1
- BYSDQZISISFLHW-UHFFFAOYSA-N n-[amino(piperazin-1-yl)methylidene]-4-[[9-chloro-7-(2-fluorophenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzamide Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C1C1=N2)=NCC1=CN=C2NC1=CC=C(C(=O)NC(=N)N2CCNCC2)C=C1 BYSDQZISISFLHW-UHFFFAOYSA-N 0.000 description 1
- NGZYRKGJWYJGRS-UHFFFAOYSA-N n-methylpyrrolidin-3-amine Chemical compound CNC1CCNC1 NGZYRKGJWYJGRS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- HAMAGKWXRRTWCJ-UHFFFAOYSA-N pyrido[2,3-b][1,4]oxazin-3-one Chemical compound C1=CN=C2OC(=O)C=NC2=C1 HAMAGKWXRRTWCJ-UHFFFAOYSA-N 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20350908P | 2008-12-22 | 2008-12-22 | |
| US203509P | 2008-12-22 | ||
| PCT/US2009/006560 WO2010074724A1 (en) | 2008-12-22 | 2009-12-15 | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2468391T3 true ES2468391T3 (es) | 2014-06-16 |
Family
ID=41664630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09795585.0T Active ES2468391T3 (es) | 2008-12-22 | 2009-12-15 | Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100183601A1 (enExample) |
| EP (1) | EP2376082B1 (enExample) |
| JP (1) | JP5738196B2 (enExample) |
| KR (1) | KR101741168B1 (enExample) |
| CN (1) | CN102264368B (enExample) |
| AU (1) | AU2009330727B2 (enExample) |
| BR (1) | BRPI0923579A2 (enExample) |
| CA (1) | CA2747326C (enExample) |
| ES (1) | ES2468391T3 (enExample) |
| MX (1) | MX2011006725A (enExample) |
| RU (1) | RU2535032C2 (enExample) |
| WO (1) | WO2010074724A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| RU2012140021A (ru) | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ |
| EP2976086B1 (en) * | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| JP6525474B2 (ja) * | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用 |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| AU2019383976B2 (en) | 2018-11-19 | 2025-07-03 | Bt Bidco, Inc. | Methods and devices for treating a disease with biotherapeutics |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| NZ192803A (en) | 1979-02-07 | 1984-08-24 | Hoffmann La Roche | Pyrimido-2-benzazepines and pharmaceutical compositions |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| TW486480B (en) | 1996-03-08 | 2002-05-11 | Zeneca Ltd | Azolobenzazepine derivatives and compositions and method of use thereof |
| JP2001507349A (ja) | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用 |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| KR100389140B1 (ko) | 1997-09-29 | 2003-06-25 | 메이지 세이카 가부시키가이샤 | 삼환성 트리아졸로벤즈아제핀 유도체 및 그의 제조방법 및항알레르기제 |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| JP2003513012A (ja) * | 1999-08-11 | 2003-04-08 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 |
| CA2390412A1 (en) * | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| WO2001052353A2 (en) * | 2000-01-12 | 2001-07-19 | Emag Technologies L.L.C. | Low cost compact omni-directional printed antenna |
| WO2001080884A1 (en) * | 2000-04-25 | 2001-11-01 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| CA2432799C (en) | 2000-12-21 | 2008-08-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| AU2002328999B8 (en) | 2001-08-09 | 2008-06-05 | Actelion Pharmaceuticals Ltd. | Novel benzo-fused heterocycles as endothelin antagonists |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| BRPI0317717B8 (pt) | 2002-12-24 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, e uso de um composto |
| WO2004071507A1 (en) | 2003-02-17 | 2004-08-26 | Pharmacia Italia S.P.A. | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20050025605A1 (en) * | 2003-07-30 | 2005-02-03 | Vrana John J. | Locator stud and method of assembly |
| SI1663242T1 (sl) | 2003-08-07 | 2011-09-30 | Rigel Pharmaceuticals Inc | 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| HRP20080120T5 (hr) | 2004-05-14 | 2012-07-31 | Millennium@Pharmaceuticals | Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze |
| JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| EP1781653A1 (en) | 2004-07-05 | 2007-05-09 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
| ATE485300T1 (de) | 2004-07-16 | 2010-11-15 | Sunesis Pharmaceuticals Inc | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| WO2006055528A2 (en) | 2004-11-15 | 2006-05-26 | Rigel Pharmaceuticals, Inc. | Process for the preparation of an optically acitive n-carbamate protected beta-lactam by optical resolution employing a candida antarctica lipase |
| CA2587427A1 (en) | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| JP2008526723A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
| JP5507049B2 (ja) | 2004-12-30 | 2014-05-28 | アステックス、セラピューティックス、リミテッド | 医薬品 |
| WO2006070202A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
| US20080312223A1 (en) | 2004-12-30 | 2008-12-18 | Astex Therapeutics Limited | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases |
| US7485661B2 (en) | 2005-01-18 | 2009-02-03 | Pfizer Italia S.R.L. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
| US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| CA2622352C (en) | 2005-09-30 | 2014-05-27 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| WO2007056163A2 (en) | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| KR20080083680A (ko) * | 2005-12-23 | 2008-09-18 | 스미스클라인 비참 코포레이션 | 오로라 키나제의 아자인돌 억제제 |
| CN100346830C (zh) * | 2005-12-28 | 2007-11-07 | 上海交通大学医学院附属瑞金医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| US7820821B2 (en) * | 2006-02-10 | 2010-10-26 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
| TW200808311A (en) | 2006-03-30 | 2008-02-16 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
| WO2007132220A1 (en) | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder |
| WO2007132221A1 (en) | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combined anticancer pyrimidine-thiazole aurora kinase inhibitors |
| GB0609530D0 (en) | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
| CA2656393A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
| EP2054413A2 (en) * | 2006-08-09 | 2009-05-06 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090023743A1 (en) * | 2007-05-09 | 2009-01-22 | Abbott Laboratories | Inhibitors of protein kinases |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| EP2496604B1 (en) * | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
| RU2012140021A (ru) * | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ |
-
2009
- 2009-12-15 WO PCT/US2009/006560 patent/WO2010074724A1/en not_active Ceased
- 2009-12-15 MX MX2011006725A patent/MX2011006725A/es active IP Right Grant
- 2009-12-15 AU AU2009330727A patent/AU2009330727B2/en not_active Ceased
- 2009-12-15 CN CN200980152195.9A patent/CN102264368B/zh not_active Expired - Fee Related
- 2009-12-15 KR KR1020117016859A patent/KR101741168B1/ko not_active Expired - Fee Related
- 2009-12-15 CA CA2747326A patent/CA2747326C/en not_active Expired - Fee Related
- 2009-12-15 RU RU2011130566/15A patent/RU2535032C2/ru active
- 2009-12-15 EP EP09795585.0A patent/EP2376082B1/en active Active
- 2009-12-15 US US12/638,018 patent/US20100183601A1/en not_active Abandoned
- 2009-12-15 JP JP2011542127A patent/JP5738196B2/ja active Active
- 2009-12-15 BR BRPI0923579A patent/BRPI0923579A2/pt not_active Application Discontinuation
- 2009-12-15 ES ES09795585.0T patent/ES2468391T3/es active Active
-
2016
- 2016-02-25 US US15/052,966 patent/US20160271249A1/en not_active Abandoned
- 2016-12-22 US US15/387,740 patent/US10391100B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102264368B (zh) | 2014-09-10 |
| US10391100B2 (en) | 2019-08-27 |
| AU2009330727A1 (en) | 2011-07-07 |
| BRPI0923579A2 (pt) | 2020-01-14 |
| CA2747326C (en) | 2017-05-16 |
| JP5738196B2 (ja) | 2015-06-17 |
| MX2011006725A (es) | 2011-09-15 |
| CN102264368A (zh) | 2011-11-30 |
| US20160271249A1 (en) | 2016-09-22 |
| EP2376082B1 (en) | 2014-03-05 |
| AU2009330727B2 (en) | 2016-07-28 |
| EP2376082A1 (en) | 2011-10-19 |
| RU2011130566A (ru) | 2013-01-27 |
| JP2012513390A (ja) | 2012-06-14 |
| US20170296551A1 (en) | 2017-10-19 |
| US20100183601A1 (en) | 2010-07-22 |
| KR101741168B1 (ko) | 2017-05-29 |
| RU2535032C2 (ru) | 2014-12-10 |
| KR20110114586A (ko) | 2011-10-19 |
| HK1160766A1 (en) | 2012-08-17 |
| CA2747326A1 (en) | 2010-07-01 |
| WO2010074724A1 (en) | 2010-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2468391T3 (es) | Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20 | |
| US9629850B2 (en) | Combination of MEK inhibitors and selective inhibitors of Aurora A kinase | |
| CN112771054B (zh) | 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物 | |
| ES2384123T3 (es) | Compuestos para inhibir la progresión mitótica | |
| ES2558742T3 (es) | Compuestos inhibidores de PI3K de benzoxepina y métodos de uso | |
| AU2022203810B2 (en) | Methods of treating and preventing alloantibody driven chronic graft versus host disease | |
| US20180117060A1 (en) | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase | |
| CA2691587A1 (en) | Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a] pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4, tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepin | |
| IT201800004082A1 (it) | Composizioni farmaceutiche antitumorali per terapia combinata | |
| HK1196296B (en) | Combination of mek inhibitors and selective inhibitors of aurora a kinase | |
| HK1220901B (en) | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase | |
| HK40052499A (en) | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |